Valneva: share price in demand on eve of earnings release
Analysts at Portzamparc announced this morning that they had added the stock to their 'High Five' list of preferred small and mid-caps, alongside Entech, Trigano, Vetoquinol and Wavestone.
In a note, the research firm cites "very good momentum" in sales of travel vaccines, and gives a 95% chance of a positive opinion from the US FDA on its chikungunya vaccine.
The research firm has issued a buy recommendation and a price target of 9.5 euros, suggesting a potential upside of 62%.
Valneva shares, up 16% over the past month, were up 3.3% around 11:30 a.m., the second-best performer in the SBF 120 index behind Fnac Darty.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction